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The host’s immune response to hepatitis C virus (HCV) can result in the selection of char-
acteristic mutations (adaptations) that enable the virus to escape this response. The ability
of the virus to mutate at these sites is dependent on the incoming virus, the ﬁtness cost
incurred by the mutation, and the beneﬁt to the virus in escaping the response. Studies
examining viral adaptation in chronic HCV infection have shown that these characteristic
immune escape mutations can be observed at the population level as human leukocyte
antigen (HLA)–speciﬁc viral polymorphisms. We examined 63 individuals with chronic
HCV infection who were infected from a single HCV genotype 1b source. Our aim was to
determine the extent to which the host’s immune pressure affects HCV diversity and the
ways in which the sequence of the incoming virus, including preexisting escape mutations,
can inﬂuence subsequent mutations in recipients and infection outcomes. Conclusion:
HCV sequences from these individuals revealed 29 signiﬁcant associations between speciﬁc
HLA types within the new hosts and variations within their viruses, which likely represent
new viral adaptations. These associations did not overlap with previously reported adapta-
tions for genotypes 1a and 3a and possibly reﬂected a combination of constraint due to
the incoming virus and genetic distance between the strains. However, these sites
accounted for only a portion of the sites in which viral diversity was observed in the new
hosts. Furthermore, preexisting viral adaptations in the incoming (source) virus likely
inﬂuenced the outcomes in the new hosts. (HEPATOLOGY 2011;53:396-405)
A
fter infection with hepatitis C virus (HCV),
outcomes are variable: spontaneous resolution
of the infection is observed in approximately
30% of individuals, but for others, chronic infection
develops. Factors such as age, gender, and host genetic
variants have been associated with different infection
outcomes
1,2 (reviewed by Rauch et al.
3). Study cohorts
that capture all individuals exposed to the virus, such as
HCV single-source outbreak cohorts
4,5 and cohorts of
individuals who have a high risk of HCV exposure,
6
have been particularly important in delineating relevant
viral and host factors associated with the outcome of
HCV infection. Such studies corroborate other studies
indicating that a host’s T cell response to HCV, includ-
ing genes involved in regulating this response, is an im-
portant correlate of infection outcome.
7-11
Abbreviations: HCV, hepatitis C virus, HLA, human leukocyte antigen, IL-28B, interleukin-28B, MHC, major histocompatibility complex, NS, nonstructural,
OR, odds ratio, SNP, single-nucleotide polymorphism.
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396T cell immune responses are stimulated by the pre-
sentation of processed viral peptides (epitopes) by
human leukocyte antigen (HLA) molecules to CD4
þ
and CD8
þ T cells. This host-virus interaction is de-
pendent on the sequence of the viral epitope and sur-
rounding regions, which play a role in peptide process-
ing and presentation to T cells. Viral adaptations can
reduce the binding afﬁnity of the peptide to the HLA
molecule and result in poor peptide cleavage or poor
T cell recognition; these factors can subvert host immune
control (reviewed by Bowden and Walker
12). The impor-
tance of immune control in HCV infection has been
illustrated in studies showing that mutations in CD8
þ T
cell epitopes contribute to viral persistence in both chim-
panzees and humans.
13,14 Accordingly, the extent to
which the virus can adapt to the host’s immune response
is likely to be an important factor in determining infec-
tion outcome. These adaptations are dependent on the
sequence of the incoming virus and the balance between
the ﬁtness cost incurred by these mutations
15 and their
beneﬁt to the virus due to immune escape.
It is unclear how much genetic diversity observed in
HCV is the result of host immune pressures. Recent
studies have suggested that viral adaptation can be
observed at both the individual level
16,17 and the pop-
ulation level.
18,19 For example, genetic studies examin-
ing HCV sequences in the context of the HLA reper-
toire of a host population have shown associations
between speciﬁc polymorphisms across the viral genome
and HLA types within individuals in a host popula-
tion.
18,19 These HLA-associated viral polymorphisms
are thought to represent viral adaptations and tag
regions of the viral genome that are under in vivo
T cell pressure. However, HCV evolution is shaped by
evolutionary forces that include genetic drift and both
positive and purifying selection pressures.
20,21 It is likely
that all these factors exert their inﬂuence simultaneously
on the virus and affect the ability of the virus to adapt
to new selection pressures and/or revert in a new host.
A previous study of an Irish HCV single-source cohort
showed evidence of immune selection in known T cell
targets.
22 In this study, we compared HCV sequences
from 63 individuals with genotype 1b infection from this
single-source outbreak
5 to identify sites likely representing
new T cell targets in the HCV genome and to determine
the extent to which host immune pressures on the virus
affected sequence diversity in the cohort. Knowledge of
the incoming viral sequence also allowed us to determine
whether preexisting viral adaptations could predict beneﬁ-
cial or detrimental host HLA alleles within the cohort
with respect to infection outcomes.
Patients and Methods
Study Population. The study population was part of
a cohort of women who had been infected with HCV
between May 1977 and November 1978 in Ireland
through the administration of anti-D immunoglobulin
that had been contaminated with an HCV genotype 1b
virus originating from a single individual.
5 From this origi-
nal cohort, we studied 63 individuals with chronic HCV
infection; a subset (n ¼ 15) was selected on the basis of
the carriage of HLA-A*03, an allele that was previously
s h o w nt ob ep r o t e c t i v ei nt h i sc o h o r t .
8 Ac o m p a r i s o no f
the HLA alleles found in this cohort and those in another
Irish population is in the Supporting Information.
Serum samples from the subjects were collected
between 1996 and 2002 and were stored at  80 C.
Written, informed consent was obtained from partici-
pants, and local institutional review board approval
was obtained by all centers contributing to the study.
Viral RNA Extraction. Viral RNA was extracted
from serum samples with the QIAamp Viral RNA
mini kit (Qiagen) or the Cobas Amplicor HCV speci-
men preparation kit (version 2.0, Roche) according to
each manufacturer’s instructions.
HLA Genotyping. Two-digit resolution HLA class I
(HLA-A, HLA-B, and HLA-C) typing was performed
at St. James Hospital (Dublin, Ireland).
8
Interleukin-28B (IL-28B) Genotyping. Genotyping
of the single-nucleotide polymorphism (SNP)
rs12979860 upstream of the IL-28B gene was per-
formed for 34 subjects as previously described.
23
Bulk Viral Sequencing. HCV sequencing was per-
formed as previously described.
18,19 Brieﬂy, three sepa-
rate reverse-transcription PCRs were performed which
overlapped to cover the core to nonstructural (NS) 5B
region. The ﬁrst-round products were used as tem-
plates in nested second-round polymerase chain reac-
tions containing generic or genotype-speciﬁc primers.
Amplicons were bulk-sequenced with the BigDye
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HEPATOLOGY, Vol. 53, No. 2, 2011 MERANI ET AL. 397Terminator version 3.1 cycle sequencing kit (Applied
Biosystems) according to the manufacturer’s recom-
mendations, and electropherograms were edited with
Assign (Conexio Genomics). Mixtures were identiﬁed
in which the secondary peak was greater than 20% of
the main peak.
HCV sequences in this study have been submitted
to GenBank (accession numbers HM106522 to
HM106981). Supporting Information Table 1 lists the
mean sequence coverage by protein.
An analysis of the viral sequences for testing the sin-
gle-source nature of this outbreak can be found in the
Supporting Information.
Ultradeep Sequencing. To identify minor quasispe-
cies below the detection threshold of bulk sequencing
methods, ultradeep sequencing was carried out with
the 454 Life Sciences platform (Roche Applied Sci-
ence) for two individuals (HLA-A*03
þ/HLA-B*08
 
and HLA-A*03
 /HLA-B*08
 ). With the previously
described ampliﬁcation method, polymerase chain
reaction templates were obtained that covered NS3
(positions 3494-4530) and NS5A to NS5B (positions
7335-8356). Amplicons were quantiﬁed and pooled
for each individual. Library preparation and sequenc-
ing were performed according to the manufacturer’s
protocol. Data were collected and analyzed with Roche
and public license software programs. All sequence
reads were aligned to the source sequence (AF313916)
with GS Reference Mapper software (Roche). The
threshold for mixtures was set at 1% with 100-fold or
greater coverage.
HLA-Associated Viral Polymorphisms. Associations
between HLA alleles and amino acid distributions at
each residue of the HCV proteins were assessed with
Fisher’s exact test for classiﬁcation as consensus or non-
consensus amino acid. A false discovery rate analysis
was carried out, and q values were obtained as
reported previously.
19 Only sequences with  50%
sequence coverage for each respective protein were
used. Analyses were carried out with Spotﬁre Sþ 8.1
(TIBCO, Somerville, MA). Associations with a P value
 0.01 for Fisher’s exact test of consensus versus non-
consensus are reported. An assessment of possible con-
founding by founder effects via viral cluster stratiﬁca-
tion and the Mantel-Haenszel procedure, as described
by Rauch et al.,
19 indicated that no correction for sig-
niﬁcant associations was necessary, and this was con-
sistent with the sequences originating from a single
source. In addition, because P values associated with
relatively small frequencies can be affected by small
numbers of misclassiﬁed cases, we restricted our analy-
sis to associations for which there were ﬁve or more
nonconsensus amino acids and ﬁve or more carriers of
the HLA allele.
Sliding-Window Analysis. In order to identify viral
escape that might not be captured with a single amino
acid approach, an analysis was conducted as described
previously, except that adaptation was deﬁned as non-
consensus at any residue within sliding windows of
nine amino acids, which represented typical peptide
sizes for HLA class I molecules. Signiﬁcant sites of
associations were identiﬁed as strings of signiﬁcant val-
ues, whereas the window slid over any residues con-
taining strong associations or combinations of associa-
tions. We restricted the analysis to cases that had all
amino acids in the window. Associations with P  
0.01 were reported.
Covariation. Residue covariation was assessed with
Fisher’s exact test for classiﬁcation as consensus or non-
consensus amino acid. Covariation based on a
sequence with  90% coverage was reported; covarying
sites had P   0.001 for amino acid versus amino acid
comparison and P   0.0001 for amino acid versus nu-
cleotide comparison. Because of the exploratory nature
of this part of the analysis, no adjustment was made
for multiple comparisons.
Peptide Prediction for HLA-Associated Viral Poly-
morphism Sites. Flanking sequences of the identiﬁed
HLA-associated viral polymorphisms and sites of com-
mon divergence from the source sequence were entered
into the epitope prediction software SYFPEITHI
24 to
identify putative epitopes based on a cutoff score of 20
with the highest scoring peptide reported. HLA-associ-
ated viral polymorphism sites were compared against
published genotype 1 epitopes found in the Immune
Epitope Database (http://www.immuneepitope.org).
Viral Sequence Diversity. Sequence diversity from
the source sequence (AF313916) was determined with
the Highlighter program (available at http://www.lanl.
gov) for NS3 and NS5B to identify sites of synony-
mous and nonsynonymous substitutions for sequences
with greater than 50% sequence coverage. Genetic di-
versity was determined with the Kimura two-parameter
model, and differences in the rate of nonsynonymous
and synonymous changes (ds/dn) were obtained with
the modiﬁed Nei and Gojobori method with MEGA
version 3.1.
25
IL-28B–Associated Viral Polymorphisms. We
assessed associations between the presence or absence
of the minor allele rs12979860 and consensus or
nonconsensus amino acids at each residue of the
HCV proteins via Fisher’s exact test. Because of the
smaller number of subjects with typing available
for this part of the analysis, no assessment of false
398 MERANI ET AL. HEPATOLOGY, February 2011discovery rates was made, and P   0.01 was used to
indicate signiﬁcance.
Results
HLA-Associated Viral Polymorphisms: Putative
Viral Adaptations in the New Hosts Reﬂecting Sites
of Immune Pressure. We determined whether there
were associations between the expression of particular
HLA alleles in subjects in this cohort and speciﬁc
polymorphisms in their viral sequences (putative viral
adaptations) reﬂecting areas under in vivo T cell
immune pressure. We identiﬁed 29 HLA-associated
viral polymorphisms with P   0.01 for 23 sites along
the HCV genome (Table 1 and Supporting Informa-
tion Fig. 3). In some instances, HLA alleles from differ-
ent loci were associated with the same site, and we have
previously shown that these associations can be explained
in part by the linkage disequilibrium observed within
the major histocompatibility complex (MHC).
18 Among
those associations shown in Table 1, three HLA-B/C
combinations are associated with common MHC haplo-
types. The q values for associations within some of the
proteins are high with respect to others (particularly E2)
and possibly reﬂect smaller sample sizes in these proteins
(Supporting Information Table 1).
Two HLA-associated viral polymorphisms fell within
previously published epitopes (HLA-A*02 epitope in
E2 404 SLLAPGAKQNV and HLA-A*03 epitope in
NS5B 2518 SLTPPHSAK; Table 1). Furthermore, three
HLA-associated viral polymorphisms fell within pre-
dicted epitopes as determined by the peptide binding
prediction program SYFPEITHI
24 (Table 1). The lim-
ited number of matches between known epitopes and
putative viral adaptation sites may be the result of the
small number of published HCV epitopes in the litera-
ture and its focus on common HLA types. Several of
the putative viral adaptations are associated with HLA-C
alleles for which there are either no or few known HLA-
restricted epitopes or characterized binding properties.
Table 1. HLA Class I-Associated Viral Polymorphisms
Protein Residue
Source
Amino
Acid
Cohort
Amino
Acidy
Variant Amino
Acid in
the Cohort HLA OR P Value q Value Sliding Window*
Predicted
Epitope
Published
Epitope
E1 299 E E V/R/Q/L/K C*16 24.00 0.003 0.298 291, 292, 298, 299
373 I I V C*16 18.00 0.006 0.357 365
E2
393 A A G C*06 11.00 0.008 0.739
397 R S H/R/L/F/S/N A*01 0.05 0.010 0.739
400 A/T T A/V C*07 0.08 0.005 0.730
403 F F L A*02 30.00 0.004 0.730 SLLAPGAKQNV
405 S S T/A C*16 0.04 0.006 0.730
577 D D N/B A*01 0.12 0.010 0.739
625 T T S B*08 11.00 0.006 0.730
P7 790 F F l/I B*07 11.00 0.001 0.037 786-794
NS2
834 H H Q B*08 15.00 0.001 0.045 836-838 SPHYKVFL
951 D D N A*02 12.00 0.003 0.108 950-955
C*05 11.00 0.004 0.148
NS3 1040 L L F B*07 12.00 0.007 0.162 1036-1038
1087 T T A A*03 17.00 0.001 0.030 1083-1091 TVYHGAGTK
1088 K K R A*03 57.00 2.86   10
 6 0.000
1130 L L P/M B*14 17.00 0.009 0.245
C*08 36.00 0.001 0.035 1126-1132
1282 V V I A*02 25.00 0.005 0.128 1278 NIRTGVRTI
B*14 35.00 0.001 0.035 1282, 1283
C*08 26.00 0.002 0.060 1282, 1283
1370 I I T/V/D B*07 0.09 0.002 0.066
NS4B 1958 K K R C*08 10.00 0.009 0.059 1960
NS5A 2143 E E D C*16 17.00 0.008 0.553
NS5B
2518 K K R A*03 11.00 0.001 0.032 2520, 2521 SLTPPHSAK
C*08 9.70 0.005 0.203
2609 S S P B*35 29.00 9.30   10
 5 0.000 2605-2613
C*04 19.00 3.82   10
 4 0.019 2608-2613
2821 R R K B*18 21.00 0.005 0.203 2821-2825
For amino acids, numbering begins from the start of the polyprotein. Bold and italicized HLA alleles are likely to form part of an MHC haplotype. Underlined
amino acids are sites of interest. E2 contains HLA-associated sites that fall within the hypervariable region (393, 397, 400, 403, and 405). Amino acid difference
in two source sequences (AF313916 and DQ061375-DQ061378, which are separated by a forward slash).
*Median point.
†Consensus amino acid.
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with the ﬁndings of our previous studies examining
HLA-associated viral polymorphisms for genotype
1.
18,19 However, the previous study had a much larger
number of genotype 1a sequences in the data set than
1b sequences; because the sequences in this single-
source cohort were all genotype 1b, it was likely that
we would observe differential escape proﬁles similar to
what we had seen between genotypes 1a and 3a but to
a lesser extent between genotype 1 subtypes (1a and
1b). Furthermore, in contrast to the subjects in the
previous cross-sectional studies, the subjects in this
study were infected from a single-source strain.
Window Analysis Identiﬁes Additional Areas
Under T Cell Pressure. Areas under HLA-speciﬁc
immune pressure that can accommodate more than
one site of variation may not be detected by our initial
single amino acid approach. Accordingly, a sliding-
window analysis (with a size reﬂective of a typical
HLA class I epitope) was also performed to examine
areas under HLA-speciﬁc immune pressure in which
more than one site might be relevant for escape. As
expected, several of the HLA-associated viral polymor-
phisms identiﬁed with a single-site analysis were iden-
tiﬁed with the window analysis (Table 1). However,
the single-site associations found in highly variable
regions in E2 were not identiﬁed in the window analy-
sis, probably because of the higher level of variation
found in this region in comparison with other proteins
that may occur in some cases when the variation is not
related to adaptation (as tested here) and may hinder
the ability to ﬁnd speciﬁc HLA associations with any
change(s) within a window. There were three examples
[E2 and HLA-C*06 with a median position of 537,
odds radio (OR) ¼ 28; NS2 and HLA-B*08 within
windows of 875-878, OR ¼ 0.026-0.039; and NS5A
and HLA-B*08 with a median position of 2132, OR
¼ 26] for which the window analysis identiﬁed HLA-
associated substitutions that were not found to be sig-
niﬁcant in the single-site analysis. These cases sug-
gested that multiple sites within a target region may
be under immune pressure (Supporting Information
Fig. 4). This observation is consistent with our own
study and other studies showing different escape pro-
ﬁles within epitopes, including the immunodominant
HLA-B*08 epitope (1395-1403) in NS3
17 and the
protective HLA-B*27 epitope (2841-2849) in NS5B.
11
Overall, the number of associations found with ei-
ther the single-site analysis or the sliding-window anal-
ysis represented only a portion of the 184 variable sites
across the viral genome that ﬁt the inclusion criteria
described in the methods (18 of 163 if the highly vari-
able region in E2 is excluded because this area is likely
to also be under other strong selective pressures).
Source and Causes of Viral Adaptation. We then
examined the pattern of synonymous and nonsynony-
mous changes in these sequences to determine if puri-
fying selection was acting across the HCV genome and
potentially restricting the ability of the virus to adapt
to new selection pressures or revert to unadapted
forms. Figure 1 shows the pattern of these changes in
each individual with respect to the source within the
NS3 and NS5B proteins. It is apparent that there are
a greater number of synonymous changes with respect
to nonsynonymous changes in this region (indicating
purifying or negative selection; dS-dN for NS3 ¼
0.080 and for NS5B ¼ 0.061). Similar results were
observed for other proteins (data not shown).
Covarying Sites in the Genome Likely to Reﬂect
Networks Within the HCV Genome. As previously
suggested, purifying selection may reﬂect the existence
of covarying sites in the HCV genome.
26 Here we
identiﬁed sites of covariance by assessing amino acid
sites in a pairwise manner per protein and genome-
wide for sequences with greater than 90% sequence
coverage. Only results with P < 0.001 were reported
because adjustments for multiple comparisons were
not made in this analysis. Thirteen of 25 paired sites
of signiﬁcant covariance were within the same protein,
whereas 12 of 25 fell in different proteins. For the ma-
jority of pairs of covariant sites, one or both sites fell
at a reported HLA-associated viral polymorphism site,
within a known epitope, or at a common site of rever-
sion from the source. Four of the 25 paired sites fell at
an HLA-associated site in Table 1. In particular, two
HLA-A*03–associated sites at positions 1087 and
1088 in NS3 fell within a conﬁrmed HLA-A*03 epi-
tope in which variation at both sites is required to
restore replicative efﬁcacy (K.F., unpublished data,
2010); this reﬂects the potential compensatory nature
of these covariations.
Fig. 2 shows a linear trend for many covarying sites
suggesting that many fell in close proximity to one
another but not necessarily in the same protein. Inter-
estingly, clusters of covarying sites appeared to connect
sites across the genome and particularly other proteins
with NS5A. One group contained sites in only one
protein (NS3 sites 1644F/Y, 1647A/T, and 1656A/T),
whereas another group contained sites in three proteins
(NS2 908R/K, NS3 1173S/L, and NS5A 2279R/K).
These links may further restrict the ability of the virus
to adapt or revert quickly and suggest critical interac-
tions between the HCV proteins. We extended this
analysis to assess covariation at amino acid and
400 MERANI ET AL. HEPATOLOGY, February 2011synonymous sites to identify potential constraints on
codon usage (and subsequent amino acid changes) and
identiﬁed four amino acid sites associated with synony-
mous changes in other proteins.
Relevance of Viral Adaptations in the New Hosts
and Preexisting Ones in the Source in Infection
Outcomes. Although the host immune pressure is one
of several forces shaping HCV diversity, it is likely
that only a small number of selected viral adaptations
in the sequence may affect infection outcomes. In this
cohort, HLA-A*03 was shown to be protective,
8 and
we selected chronic HCV–infected individuals with
HLA-A*03 for this study to identify viral adaptations
in these individuals that may have affected their infec-
tion outcomes. Three viral polymorphisms were associ-
ated with HLA-A*03 in this study (Table 1). Two of
the associations were in NS3 at positions 1087 and
1088 within a predicted epitope for HLA-A*03. As
mentioned previously, this epitope was subsequently
shown to be a true in vivo target of the immune
response (NS3 1080 TVYHGAGTK; K.F., unpublished
data, 2010; Fig. 3A) and reﬂected a drop in the SYF-
PEITHI-predicted binding score from 34 for the wild
type to 21 for the putative escape peptide. Another
HLA-A*03–associated viral polymorphism at position
2518 in NS5B was within the previously characterized
genotype 1a epitope SLTPPHSAK (Fig. 3B). Half of
the HLA-A*03 individuals had a polymorphism at
these sites in both regions. These results suggest that
these two viral epitopes are important immune targets
and that escape within the targets may inﬂuence the
outcome.
Further analysis of the quasispecies at the NS3 1087
and 1088 sites in HLA-A*03
þ and HLA-A*03
  sub-
jects was performed with ultradeep sequencing. Table 2
reveals the lack of a source sequence at amino acid
position NS3 1088 in the HLA-A*03 subject with
complete amino acid replacement but 100% retention
of the source sequence in the HLA-A*03
  subject. The
two subjects had the same amino acid at position 1087
(unadapted), but codon usage was different between
the two.
Previous studies have found other HLA alleles to be
associated with chronic infection that are speciﬁc to
this cohort, such as alleles HLA-A*01, HLA-B*08, and
HLA-C*07
8 (these alleles most likely correspond to a
Fig. 1. Highlighter plot of synonymous and nonsynonymous substitutions in NS3 and NS5B with respect to the source sequence (AF313916).
The plot was created with Highlighter (available at http://www.lanl.gov). Red lines denote nonsynonymous substitutions, green lines indicate syn-
onymous substitutions, and gray regions show unsequenced sections.
HEPATOLOGY, Vol. 53, No. 2, 2011 MERANI ET AL. 401single MHC haplotype). It has been suggested that the
association between infection outcomes and speciﬁc
HLA alleles may be due to preexisting viral adapta-
tions in the incoming virus that may facilitate the eva-
sion of host immune responses with the corresponding
HLA types.
27 Here we tested this hypothesis by exam-
ining the source sequence for escape mutations within
known epitopes as well as putative viral adaptations
identiﬁed in our previous genetic study of chronic
HCV infection.
18,19
Initially, we examined the immunodominant epitope
for HLA-B*08 in NS3 (1395 HSKKKCDEL) and the
protective HLA-B*27 epitope in NS5B (2841
ARMILMTHF). The region in the source containing
the HLA-B*27 epitope in NS5B had the unmutated
form. However, the HLA-B*08 epitope in NS3 in the
source sequence had a preexisting viral adaptation in
the epitope (arginine at position 3), which subse-
quently reverted in 8 of 11 subjects without HLA-
B*08 and was retained in 5 of 8 subjects who
expressed HLA-B*08. Although the numbers in the
two groups were not signiﬁcantly different (P ¼ 0.18),
they supported other studies showing reversion from
an arginine to lysine at position 3 in this epitope
when there was no immune pressure; this is suggestive
of a ﬁtness cost.
15 This HLA-B*08 epitope was previ-
ously studied in this cohort with similar results.
15,22
The ﬁtness cost of this substitution was further sup-
ported by the results from the ultradeep sequencing of
two HLA-B*08
  subjects in this region, who showed
complete reversion from the source escape mutation at
position 3 of the epitope (Table 3).
Viral adaptation in the source sequence at a site in
the HLA-B*08 immunodominant epitope likely to
incur a ﬁtness cost suggests that the source may have
been an HLA-B*08
þ individual. We suggest that this
could potentially reduce the ability of hosts with
HLA-B*08 to control the virus via the reduction of
good immune targets, and this reﬂects the association
of this allele with poor outcomes in this cohort. Addi-
tional association sites with HLA-B*08
þ individuals
found in this study may represent alternative targets
for HLA-B*08 along the HCV genome. Furthermore,
Table 1 and Supporting Information Fig. 4 list HLA-
associated viral polymorphisms that have an OR less
than 1 and represent the maintenance of the consensus
sequence (which for most sites in Table 1 is the same
as the source) for the speciﬁc HLA type; this possibly
reﬂects that the source sequence is pre-adapted at these
sites. Interestingly, this occurs for alleles within the
MHC haplotypes HLA-A*01, HLA-B*08, and HLA-
C*07, which are associated with poor outcomes.
Other Selective Pressures Likely to Affect HCV
Evolution. In order to determine how other host
immune pressures may affect HCV evolution, we
assessed possible associations between HCV polymor-
phisms in this cohort and an SNP that tags the
Fig. 2. Covarying sites (P < 0.001) in the HCV genome repre-
sented as coordinates. Open diamonds indicate that one or both sites
fall within an epitope or at an association site, and dark diamonds
indicate that the sites do not fall within either. Many covariant sites
fall in close proximity to one another in the genome (illustrated by the
linear trend); however, there are groupings that suggest strong covaria-
tion between residues within NS5A and residues within other proteins.
Sequence coverage was not found to be a function of covariant site
identiﬁcation.
Table 2. Ultradeep Sequencing Reveals a Lack of a Source
Sequence at Putative Viral Adaptation Sites (NS3 1087 and
1088) in a Subject With HLA-A3 but 100% Maintenance of
the Source Sequence in an HLA-A3
2 Subject
Sequence
Position HLA
^
1087 1088 A*03
1 A*03
2
Source T K 0 346
ACAAAG
Variant 1 TK 0 685
ACTAAG
Variant 2 TR 249 0
ACAAGG
Variant 3 TR 1111 0
ACGAGG
The HLA-A3
þ subject carried only species that differed at the amino acid
level from the source. Although the two subjects had the same amino acid at
position 1087, codon usage was different. The region had more than 1000-fold
coverage.
^Number of sequence reads with a corresponding variant or source
combination.
402 MERANI ET AL. HEPATOLOGY, February 2011Table 3. Ultradeep Sequencing Reveals a Lack of a Source Sequence at Position 1397 in the Immunodominant HLA-B*08
Epitope in NS3 (HSKKKCDEL) in Two HLA-B*08
2 Subjects
Sequence
Position HLA*
1397 1398 1399 A*03
1/B*08
2 A*03
2/B*08
2
Source R K K 0 0
AGGAAAAAA
Variant 1 KKK 526 358
AAGAAGAAA
*Number of sequence reads with a corresponding variant or source combination.
Fig. 3. HLA-A*03–associated viral polymorphisms at (A) positions 1087 and 1088 in NS3 and (B) position 2518 in NS5B. Sequences in
regions of interest (from Table 1) are displayed for HLA-A*03
þ and HLA-A*03
  subjects. The sequence identity with the source sequence is
identiﬁed by a dot. Amino acid mixtures at a site are separated by a forward slash. The number of individuals with a particular sequence is
shown in the count column. The lysine (K) to arginine (R) substitution at 2518 (8 of 15 HLA-A*03
þ subjects versus 4 of 47 HLA-A*03
  sub-
jects) resulted in a change in the SYFPEITHI-predicted binding score from 27 to 21. Only one HLA-A*03 individual with chronic infection did not
have a polymorphism at the 1087 or 1088 site in NS3 or at the 2518 site in NS5B.
HEPATOLOGY, Vol. 53, No. 2, 2011 MERANI ET AL. 403IL-28B gene encoding interferon-k3 and recently has
been associated with infection outcome.
2 We found
one signiﬁcant association between homozygosity for
the major allele of rs12979860 (associated with good
outcome) and variation at position 849 in NS2 (P ¼
0.006). We also tested for additional effects of the
IL-28B SNP on the HLA-associated polymorphisms.
After adjustments for HLA, among the positions identi-
ﬁed in Table 1, IL-28B was associated with a polymor-
phism (P ¼ 0.036) only at position 2609 of NS5B,
which harbors the strong HLA-B*35/HLA-C*04 asso-
ciation. The signiﬁcance of the HLA-B*35 association
with nonconsensus after adjustments for the IL-28B
SNP is P ¼ 0.00004, whereas for HLA-B*35 alone,
the P value is 0.0001. There was no signiﬁcant interac-
tion between the effects of HLA-B*35 and IL-28B
(P > 0.9), and this suggests that they act independently.
Further studies examining the association between varia-
tions that tag IL-28B and HCV evolution are warranted
and should be performed on larger cohorts including
subjects with different treatment and infection outcomes.
Discussion
Here we illustrate that the incoming viral sequence,
host immune pressure, and covariation play important
roles in shaping HCV viral diversity. Speciﬁcally, we
identiﬁed 29 signiﬁcant HLA-associated viral polymor-
phisms (P   0.01; 23 sites) within the cohort that
likely reﬂect viral adaptations. Some of these sites fall
within published and/or predicted T cell epitopes. The
use of a sliding-window analysis accounting for more
than a single escape variant within a T cell target iden-
tiﬁed a small number of additional potential regions
under T cell pressure, and this supported other studies
showing that escape can require the accumulation of
escape mutations
28 or that viral escape sites are often
mutually exclusive because of the ﬁtness cost.
15,18
The number of signiﬁcant HLA-associated viral
polymorphism sites identiﬁed in this study is only a
small proportion of the sites (23/184) across the HCV
genome showing variation in the cohort; this is possi-
bly due to the relatively small sample size or suggests
that the host immune pressure has a targeted inﬂuence
on HCV diversity. This would be expected because the
immune system sees the viral polyprotein as a set of
peptides, and only a small number of these peptides
are likely to be presented to the immune system. Fur-
thermore, the lack of signiﬁcant overlap with previ-
ously reported adaptations for genotypes 1a and 3a
likely reﬂects the constraint of the incoming virus and
differential viral adaptation pathways on genotype 1b
versus other circulating genotypes due to the genetic
distance between these strains. It should be noted that
although we did not show HLA class II–associated
viral polymorphisms, it is likely that, in addition to
what we observed for HLA class I alleles, some of the
variations correspond to the expression of speciﬁc
HLA class II alleles.
To appreciate the extent to which both positive and
purifying selections inﬂuence HCV diversity, we exam-
ined the number of synonymous and nonsynonymous
changes across the genome for this single-source
cohort. An abundance of synonymous changes indi-
cated purifying selection that would to some extent
limit the plasticity of HCV. Covariations that become
ﬁxed across the HCV genome may also restrict the
ability of HCV to adapt to the host’s immune
response and revert when it enters a new non–HLA-
matched host. We examined the genome for covarying
sites and showed that although covariation did occur
locally within proteins, there were also a number of
sites that were linked to sites more distant in the ge-
nome. Furthermore, several of these sites were putative
viral adaptation sites.
Access to the source viral sequence from this single-
source cohort allowed the identiﬁcation of preexisting
escape mutations across the genome. A known escape
mutation at position 3 of the immunodominant HLA-
B*08 NS3 epitope was found in the source sequence.
This mutation was for the most part retained in HLA-
B*08 subjects but had reverted in most HLA-B*08
 
subjects. Furthermore, deep sequencing revealed no
traces of the escape mutant in two B*08
  individuals,
and this supports the ﬁtness cost that may be incurred
by the escape mutation. Importantly, existing adapta-
tion in the incoming virus may affect infection out-
comes in individuals expressing the appropriate HLA
type. The pre-adaptation of the source sequence to
HLA-B*08 may account for the observed lack of pro-
tection of HLA-B*08 in this cohort.
The single-source cohort studied here has provided
us an opportunity to obtain a better understanding of
viral diversity and the ways in which different forces
can shape viral diversity at the population level.
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